TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of B-cell diseases, including hematologic cancers and autoimmune conditions.
The company’s lead product, BRIUMVI™ (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (RMS). In addition to BRIUMVI, TG Therapeutics has a strong pipeline of investigational therapies targeting B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
The company’s approach combines scientific rigor with a commitment to addressing unmet medical needs, particularly in areas where current treatment options are limited. TG Therapeutics’ growth strategy focuses on advancing its clinical programs, achieving regulatory milestones, and successfully launching its therapies in global markets.
With a deep pipeline, strategic partnerships, and a patient-centered approach, TG Therapeutics is positioned as a key player in the fight against B-cell diseases and continues to work toward delivering transformative treatments that improve patient outcomes.
